A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Inclusion Criteria:

• Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), byprior biopsy, based on local testing according to the WHO classification ofneoplasms of the hematopoietic and lymphoid tissues

• Has positron emission tomography (PET) positive disease at screening, defined as 4to 5 on the Lugano 5-point scale

• Has received no prior treatment for their DLBCL

• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2assessed within 7 days before randomization

• Has an ejection fraction ≥45% as determined by either echocardiogram (ECHO) ormultigated acquisition (MUGA)

• Human immunodeficiency virus (HIV) infected participants must have well controlledHIV on antiretroviral therapy (ART)

• Who are hepatitis B surface antigen (HBsAg) positive are eligible if they havereceived hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viralload prior to randomization

• Participants with history of hepatitis C virus (HCV) infection are eligible if HCVviral load is undetectable at screening

Exclusion Criteria:

• Has a history of transformation of indolent disease to DLBCL

• Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zonelymphoma

• Has Ann Arbor Stage I DLBCL

• Has clinically significant (i.e., active) cardiovascular disease: cerebral vascularaccident/stroke (<6 months prior to enrollment), myocardial infarction (<6 monthsprior to enrollment), unstable angina, congestive heart failure (New York HeartAssociation Classification Class ≥II), or serious cardiac arrhythmia requiringmedication

• Has clinically significant pericardial or pleural effusion

• Has ongoing Grade >1 peripheral neuropathy

• Has a demyelinating form of Charcot-Marie-Tooth disease

• HIV-infected participants with a history of Kaposi's sarcoma and/or MulticentricCastleman's Disease

• Has ongoing corticosteroid therapy

• Has received a live or live-attenuated vaccine within 30 days before the first doseof study intervention. Administration of killed vaccines is allowed

• Known additional malignancy that is progressing or has required active treatmentwithin the past 2 years

• Known active central nervous system (CNS) lymphoma

• Has active autoimmune disease that has required systemic treatment in the past 2years

• Has active infection requiring systemic therapy

• Has concurrent active HBV (defined as HBsAg positive and detectable HBV DNA) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA))infection

• Has history of allogeneic tissue/solid organ transplant